Systematic prediction of cellular response to perturbations is a central challenge in biology, both for mechanistic explanations and for the design of effective therapeutic interventions. We addressed this challenge using a computational/experimental method, termed perturbation biology, which combines high-throughput (phospho)proteomic and phenotypic response profiles to targeted perturbations, prior information from signaling databases and network inference algorithms from statistical physics. The resulting network models are computationally executed to predict the effects of tens of thousands of untested perturbations. We report cell type-specific network models of signaling in RAFinhibitor resistant melanoma cells based on data from 89 combinatorial perturbation conditions and 143 readouts per condition. Quantitative simulations predicted c-Myc as an effective co-target with BRAF or MEK. Experiments showed that co-targeting c-Myc, using the BET bromodomain inhibitor JQ1, and the RAF/MEK pathway, using kinase inhibitors is both effective and synergistic in this context. We propose these combinations as pre-clinical candidates to prevent or overcome RAF inhibitor resistance in melanoma.
Introduction
Drug resistance in cancer treatment. The Inhibition of key oncogenes with target specific agents elicits dramatic initial response in some cancers such as prostate cancer and melanoma Clegg et al., 2012) . Even for the most successful single agent targeted therapies, however, drug resistance eventually emerges leading to rapid progression of metastatic disease (Garraway and Janne, 2012) . The mechanism of drug resistance may involve selection of resistant sub-clones, emergence of additional genomic alterations, and compensating interactions between alternative signaling pathways (Choi et al., 2007; Huang et al., 2011; Wagle et al., 2013) . One potential solution to overcome drug resistance is to combine targeted drugs to block potential escape routes (Fitzgerald et al., 2006) . Therefore, there is currently a need for systematic strategies to develop effective drug combinations.
Drug resistance in melanoma. Targeted therapy has been particularly successful in treatment of melanoma. BRAFV600E gain-of-function mutation is observed in ~50% of melanomas (Davies et al., 2002) . Direct inhibition of BRAFV600E by the RAF inhibitor (RAFi) vemurafenib and inhibition of the downstream MEK and ERK kinases have yielded response rates of more than 50% in melanoma patients with this mutation (Chapman et al., 2011; . At the cellular level, inhibition of the ERK pathway leads to changes in expression of a set of critical cell cycle genes (e.g., CCND1, MYC, FOS) and feedback inhibitors of ERK signaling (e.g., DUSP, SPRY2) (Pratilas et al., 2009 ).
Resistance to vemurafenib emerges after a period of ~7 months in tumors that initially responded to single-agent therapy (Chapman et al., 2011; Sosman et al., 2012) . Multiple RAFi and MEKi (e.g., PD-0325901, Trametinib) resistance mechanisms, which may involve alterations in NRAS/ERK pathway (e.g., NRAS mutations, switching between RAF isoforms) or parallel pathways (e.g., PTEN loss), have been discovered in melanoma (Johannessen et al., 2010; Nazarian et al., 2010; Poulikakos et al., 2010; Xing et al., 2012) .
The alterations associated with drug resistance may pre-exist alone, in combinations or emerge sequentially and vary substantially between patients (Van Allen et al., 2014) . Effective drug combinations may target diverse resistance mechanisms. Despite anecdotal success, conventional methods and combinatorial drug screens generally fail to come up with effective combinations due to the genomic complexity and heterogeneity of tumors (Zhao et al., 2014) .
In order to more effectively nominate drug combinations, we propose to employ system-wide models that cover interactions between tens to hundreds of signaling entities and can describe and predict cellular response to multiple interventions. There have been prior attempts to construct such signaling models. De novo and data-driven quantitative models were able to cover only a few signaling interactions and therefore had limited predictive power (Nelander et al., 2008; Bender et al., 2011; Klinger et. al., 2014; Oates, et al. 2014 ). (i.e., profiled (phospho) 
Figure 1. Quantitative and predictive signaling models are generated from experimental response profiles to perturbations. Perturbation biology involves systematic perturbations of cells with combinations of targeted compounds (Box 1-2), high-throughput measurements of response profiles (Box 2), automated extraction of prior signaling information from databases (Box 3-4), construction of ODE-based signaling pathway models (Box 5) with the belief propagation (BP) based network inference algorithm (Box 6) and prediction of system response to novel perturbations with the models and simulations (Box 7). The "prior extraction and reduction algorithm" (PERA) generates a qualitative prior model, which is a network of known interactions between the proteins of interest

proteins). This is achieved through a search in the Pathway Commons information resource, which integrates biological pathway information from multiple public databases (Box 3-4). In the quantitative network models, the nodes represent measured levels of (phospho)proteins or cellular phenotypes and the edges represent the influence of the upstream nodes on the time derivative of their downstream effectors. This definition corresponds to a simple yet efficient ODE-based mathematical description of models (Box 5). Our BP-based modeling approach combines information from the perturbation data (phosphoproteomic and phenotypic) with prior information to generate network models of signaling (Box 6). We execute the resulting ODE based models to predict system response to untested perturbation conditions (Box 7).
Qualitative or discrete models can cover more interactions but typically lack the capability of generating quantitative predictions (Saez-Rodriguez et al., 2009; Breitkreutz et al., 2010; Saez-Rodriguez et al., 2011) . Detailed physicochemical models derived using generic biochemical kinetics data can be quite comprehensive and quantitative but typically lack sufficient cell-type specificity required for translationally useful predictions (Chen et al., 2009 ).
We construct comprehensive, cell-type specific signaling models that quantitatively link drug perturbations, (phospho)proteomic changes and phenotypic outcomes (Figure 1 ). The models capture diverse signaling events and predict cellular response to previously untested combinatorial interventions.
In order to generate the training data for network modeling, we first perform systematic perturbation experiments in cancer cells with targeted agents. Next, we profile proteomic and phenotypic response of cells to the perturbations. The cell type-specific response data serve as the input for network inference. We also incorporate prior pathway information from signaling databases to narrow the parameter search space and improve the accuracy of the models. For this purpose, we developed a computational tool [Pathway Extraction and Reduction Algorithm (PERA)] that automatically extracts priors from the Pathway Commons signaling information resource (Cerami et al., 2011; Demir et al., 2010) .
Even in the presence of large training data and priors, network inference is a difficult problem due to the combinatorial complexity (i.e., exponential expansion of the parameter search space with linear increase of parameters). For example, to infer a network model with 100 nodes using Monte Carlo based methods, we in principle would need to cover a search space that includes ~2 (100x100) network models-a computationally impossible task. To circumvent this problem, we have adapted a network modeling algorithm based on belief propagation (BP), which replaces exhaustive one-by-one searches by a search over probability distributions Molinelli, Korkut, Wang et al., 2013) . The algorithm enables us to construct models that can predict response of hundreds of signaling entities to any perturbations in the space of modeled components.
We use prior information (signaling interactions from databases) as soft restraints on search space, i.e., the algorithm rejects interactions that do not conform to the experimental training data. To quantitatively predict cellular response to combinatorial perturbations, we simulate the fully parameterized network models with in silico perturbations until the system reaches steady state (Figure 1 and 5).
The steady state readout for each proteomic and phenotypic entity (i.e., system variables) is the predicted response to the perturbations.
We constructed cell type specific network models of signaling from perturbation experiments in RAFi-resistant melanoma cells (SkMel-133 cell line Table   S1 for drug targets and doses). The perturbations consisted of systematic paired combinations of individual agents and multiple doses of single agents. This procedure generated 89 unique perturbation conditions, which targeted specific pathways including those important for melanoma tumorigenesis such as ERK and PI3K/AKT (Haluska et al., 2006) .
Proteomic/Phenotypic Profiles.
A key aspect of the data acquisition for network inference is combining the proteomic and cellular phenotypic data so that the resulting models quantitatively link the proteomic changes to global cellular responses. Toward this objective, we profiled the melanoma cells for their proteomic and phenotypic response under 89 perturbation conditions ( Figure 2B -C). We used reverse phase protein arrays (RPPA) to collect drug response data for 138 proteomic (total and phospho-protein levels) entities in all conditions (Tibes et al., 2006) . In parallel, we measured phenotypic responses, including cell viability and cell cycle progression (i.e., G1, S, G2, G2M arrest phenotypes) in all conditions ( Figure 2B ). proteins on same or related pathways) respond similarly to targeted agents ( Figure 2C , Figure S2 ).
A description of the response map as a set of uncoupled pairwise associations between proteomic and phenotypic entities is not sufficient for achieving systematic predictions. Therefore, we built quantitative models using the experimental response map. The models describe the coupled nature of the Table S2 
Quantitative and predictive network models of signaling
Network models. Next, we used the experimental response map ( Figure 2 ) and the BP-based inference strategy ( Figure 1 ) to build quantitative network models of signaling in melanoma. In the models, each node quantifies the relative response of a proteomic or phenotypic entity to perturbations with respect to the basal condition. Consequently, proteomic entities that do not respond to even a single perturbation condition, do not contribute any constraints for inference. We eliminated such entities from the network modeling with a signal-to-noise analysis (See Supplementary Methods) and included 82 of the 138 proteomic measurements in the modeling. In addition to the proteomic nodes, the models contained 5 phenotypic nodes and 12 "activity nodes", which represent the 12 drugs and couple the effect of the targeted perturbations to the other nodes in the network. In total, network models contained 99 nodes. BP algorithm generates the probability distribution of edge strengths for every possible interaction between the nodes. The BP-guided decimation algorithm (see Methods, Figure   S1 ) instantiates distinct network model configurations from the probability model (Montanari et al., 2007) .
The mathematical formulation of the BP-based network inference is suitable for both de novo modeling (i.e. modeling with no prior information) and modeling using prior information (see Supplementary methods). Here, we used prior information to infer models with higher accuracy and predictive power compared to de novo models. Using the PERA computational tool, we derived a generic prior information model from Reactome and NCI-Nature PID databases, which were stored in Pathway Commons (Cerami et al., 2011) . The prior information network contains 154 interactions spanning multiple pathways ( Figure S3 ). Next, we added a prior prize term to the error model (Equation S1) to restrain the search space by favoring the interactions in the prior model. It is critical that the prior information does not overly restrain the inferred models and the algorithm can reject incorrect priors. To address this problem, we inferred network models using the pathway driven and randomly generated prior restraints. The statistical comparison of the networks inferred with actual (i.e., reported in databases) and random prior models indicated that the inference algorithm rejected significantly higher number of prior interactions when randomly generated priors were used for modeling ( Figure S3 ). Finally, we integrated the experimental data and prior information to generate 4000 distinct and executable model solutions with low errors using the BP-based strategy.
Use of prior information improves the predictive power of models
Cross validations with and without prior information We addressed the question whether BP-derived models have predictive power and whether use of prior information introduces further improvement. To assess the predictive power of the network models (i.e. predicting the response to untested perturbations), we performed a leave-k-out cross validation ( Figure 3A ). In two separate validation calculations, we withheld the response profile to every combination of either RAFi or AKTi (leave-11-out cross validation). This procedure created a partial training dataset that contains response to combinations of 11 drugs and 2 different doses of a single drug totaling to 78 unique conditions (Table S2 ).
First, we constructed both de novo (i.e. without any prior information) and prior information guided network models with each partial dataset. Next, we predicted the response by executing the models with in silico perturbations that correspond to the withheld experimental conditions. Finally, we compared the hidden and predicted response data from models generated de novo or with prior information.
Restraining inference with prior information improves the predictive power of models. The comparison between the predicted and the withheld experimental profiles suggests that the de novo network models have considerable predictive power and the use of prior information in modeling Figure S3 for analysis of the edge distribution in models). As a first step of detailed analysis and for the purpose of intuitive interpretation, we computed an average network model ( Figure 4A ), which is However, a CDK4 and PKC inhibitors substantially reduced SkMel-133 cell viability only at high doses, as in the original perturbation experiments (> 2 µM) ( Figure S5 ). More importantly, the simulations allowed us to identify effective perturbation combinations that cannot be trivially deduced from the experimental data (Table 1, Figure 5D -H, figures S4).
A thorough analysis of all the predicted responses identified the top responding targets in SkMel133 cells. In particular, in silico perturbations of c-Myc lead to the strongest G1-arrest response when co-targeted with BRAF, MEK and cyclin D1 ( Figure 5D-H, Figure 6A ). Consistent with the vast literature on c-Myc's role in genesis of many cancers (Dang, 2012) , predictions indicated that c-Myc linked multiple pathways such as ERK and PI3K/AKT to regulation of cell cycle arrest (Table 1) . As neither c-Myc nor its direct regulators were inhibited in the perturbation experiments, the predictions from the models were nontrivial and we decided to test these predictions experimentally. Figure 5D -H, Table S4 and Figure S4 . Figure S4 . ______________________________________________________________
Figure 5 Simulations with in silico perturbations provide predictions on system response to novel perturbations. A. The schematic description of network simulations. The system response to paired perturbations is predicted by executing the ODE-based network models with in silico perturbations. In the ODE based models, {W ij } represents the set of interaction strengths and is inferred with the BP-based modeling strategy. The in silico perturbations are applied as real valued u i m vectors. The time derivative and final concentration of any predicted node is a function of the model parameters, the perturbations and the values of all the direct and indirect upstream nodes in the models
Co-targeting c-Myc with MEK or RAF is synergistic in melanoma cells
We predicted through quantitative simulations that melanoma cells were arrested in G1-phase of the cell cycle when c-Myc was targeted alone or in combination with other proteins, particularly BRAF, MEK and cyclin D1 ( Figure 6A ). We experimentally tested the key prediction from the network models. In order to target c-Myc expression, we treated melanoma cells with the BET bromodomain inhibitor, JQ1, as a single agent and in combination with MEKi (PD-0325901) or RAFi (vemurafenib). JQ1 directly targets bromodomains, especially those of the bromodomain protein BRD4, which marks select genes including MYC on mitotic chromatin. Inhibition of the BRD4 bromodomains with JQ1 downregulates MYC mRNA transcription and leads to G1 cell cycle arrest in diverse tumor types, such as multiple myeloma (Delmore et al., 2011; Loven et al., 2013; Puissant et al., 2013) .
First, we asked whether we could affect c-Myc levels in SkMel-133 cells using BRAFV600E mutation) to another BRD4 inhibitor, MS417 (Segura et al, 2013) .
The observed sensitivity is also comparable to those of multiple myeloma and MYCN-amplified neuroblastoma cell lines, reported to be potentially JQ1-sensitive tumor types (Delmore et al., 2011; Puissant et al., 2013) , and substantially higher than those of lung adenocarcinoma and MYCN-WT neuroblastoma cell lines (Lockwood et al., 2012; Puissant et al., 2013) .
We tested the effect of combined targeting of c-Myc with MEK or BRAF on cell viability in SkMel-133 cells ( Figure 6D ). Strikingly, when combined with JQ1 (120nM), cell viability is reduced by 50% with 120 nM of RAFi (PLX4032), whereas the IC50 for single agent RAFi is >1 µM in RAFi-resistant SkMel-133 cells. Similarly, when combined with 5 nM MEKi (PD901), viability of SkMel-133 cells is reduced by 50% with 100 nM of JQ1, an IC50 value, which is close to those of the most sensitive multiple myeloma cell lines (Delmore et al, 2011) . At JQ1, MEKi, RAFi and their combinations (24 hours) 
B. RAFi inhibits MEK phosphorylation at S217 and MEKi inhibits ERK phosphorylation at T202 in a dose dependent manner (first 2 gels). Western blot showing the level of c-Myc in response to
IC50 (Cell viability) Combined with JQ1
5nM** 120nM** *MEKi targets pERK and RAFi targets pMEK. Phopho-IC50s are quantified from gels ( Figure 6B ). **IC50s for viability and phosphorylation are in same order.
Discussion
We generated network models of signaling in melanoma cells to systematically predict cellular response to untested drug perturbations. Our modeling algorithm integrates high-throughput drug response profiles and pathway information from signaling databases. The scale and the predictive power of the models are beyond the reach of the currently available network modeling methods. Based on the predictions from models, we found that co-targeting MEK or BRAF with c-Myc leads to synergistic responses to overcome RAF inhibitor resistance in melanoma cells. Beyond nomination of effective drug combinations, the perturbation biology method paves the way for model-driven quantitative cell biology with diverse applications in many fields of biology.
Cell type specificity. In network modeling, the experimental data provides the cell type-specific constraints while the priors introduce a probabilistic bias for background signaling information. Consequently, the network models are cell type specific and not only recapitulate known biology but also predict novel interactions. Moreover, the algorithm rejects a significant part of the interactions in the prior model. For example, the influences of cyclin E1 and cyclin D1 on RB phosphorylation are well known (Akiyama et al., 1992; Kato et al., 1993) p16Ink4A, directly inhibits cyclin D1/CDK4 as it participates in a G1 arrest checkpoint (Serrano et al., 1993) . On the other hand, the alternative CDKN2A gene product, p14ARF can inhibit the cyclin E1/CDK2 complex only indirectly through an MDM2/TP53/p21Cif1 dependent pathway and CDKN2A gene products appear to have no direct influence on cyclin E1 (Giono and Manfredi, 2007; Stott et al., 1998) . In SkMel-133 cells, the homozygous deletion in CDKN2A most likely leads to excessive cyclin D1/CDK4 catalytic activity, which may override the influence of cyclin E1 /CDK2 complex on RBpS807. The descriptive aspect of the inferred models is of course inherently limited to the 99 components (nodes) included in models and constrained by data or prior information.
Co-Targeting c-Myc and ERK signaling. Oncogenic alterations that decrease drug sensitivity may pre-exist in combinations or emerge sequentially in a tumor.
In general, it is likely that tumors can escape therapy through alternative routes, rendering countermeasures difficult. One potential counter strategy is to identify and target proteins, on which multiple drug resistance pathways converge.
Through quantitative simulations, we have predicted that c-Myc couples multiple signaling pathways such as MAPK and AKT to regulation of cell cycle arrest in SkMel-133 cells (Table 1) . According to the predictions, co-targeting c-Myc with MEK, BRAF or cyclin D1 leads to the highest impairment in tumor growth. To test our predictions, we targeted c-Myc using the epigenetic drug JQ1, a BRD4
inhibitor that negatively effects c-Myc transcription. We treated cells with combinations of JQ1 and MEKi or RAFi. We showed that both combinations lead to synergistic cell viability response with particularly improved outcomes in high doses (lower A max ). A hallmark of high pharmacological efficacy is a drug's ability to induce cellular response at doses sufficient to inhibit the immediate molecular targets. In SkMel-133 cells, however, the cell viability IC50s for RAFi and MEKi are at least one order of magnitude higher than the doses required to reduce the phosphorylation of immediate downstream targets (phospho-MEK and phospho-ERK, respectively) by 50% ( Figure 6B , Table 2 ) and hence the cells are resistant to both drugs. When combined with JQ1, RAFi/MEKi doses, which are sufficient to reduce cell viability by 50%, are in the range of MEK and ERK phosphorylation IC50s (Table 2) . Thus, the JQ1-MEKi/RAFi combinations shift the required doses to induce a cellular response close the doses required for inhibition of ERK pathway activity. Recently, it is reported that JQ1 and FLT3 tyrosine kinase inhibitor (TKI) combination shows synergy to overcome FLT3-TKI in AML cells (Fiskus et al., 2014) . As far as we know, this is the first demonstration of a combined inhibition of a BET bromodomain protein and a protein kinase molecule to overcome drug resistance in solid tumors (Filippakopoulos and Knapp, 2014) .
Targeting c-Myc can be highly toxic since c-Myc functions as a key transcription factor almost in all normal tissues and tumors (Soucek et al., 2008) . MEK inhibitors are also highly toxic and their toxicity can only be managed with dose interruption and reduction . Use of synergistic drug combinations offers a potential solution to the drug toxicity problem as the drug doses in such combinations are substantially low compared to the doses in the single agent treatments. We conclude that co-targeting c-Myc and ERK pathway has the potential to go beyond single agent treatments in overcoming drug resistance and lowering drug toxicity in melanomas in genomic contexts similar to that in this study. Tables S1 and S3 for (Table S3) . Mathematical description of network models. The network models represent the time behavior of the cellular system in a set of perturbation conditions as a series of coupled nonlinear ordinary differential equations (ODE) (Nelander et al., 2008) .
Equation 1. Network model ODEs
In Network model construction and response prediction Network models are constructed with a two-step strategy. The method is based on first calculating probability distributions for each possible interaction at steady state with the Belief Propagation (BP) algorithm and then computing distinct solutions by sampling the probability distributions. We described the theoretical formulation, the underlying assumptions and simplification steps of the BP algorithm for inferring network models of signaling elsewhere (Molinelli, Korkut, Wang et al., 2013) . The network models include 82 proteomic, 5 phenotypic and 12 activity for derivation and implementation of BP equations).
BP-guided decimation Distinct networks models are instantiated from BP generated probability distributions with the BP-guided decimation algorithm ( Figure S1 ) (Montanari et al., 2007) . This procedure generates distinct and executable network models. In this study, 4000 distinct network models are generated in each computation.
Simulations with in silico perturbations. Network models are executed with specific in silico perturbations until all system variables {x i } reach steady state.
The perturbations acting on node i are exerted as real-valued u i µ vectors in model equation 1. The DLSODE integration method (ODEPACK) (Hindmarsh, 1993 ) is used in simulations (default settings with, MF =10, ATOL= 1e-10, RTOL=1e-20).
